Ferrous Fumarate
Iron Bivalent, Oral Preparations
Sold as Integra F
- Drug class
- Iron Bivalent, Oral Preparations
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 7
- FDA reports (12 mo)
- 331
Overview
Ferrous Fumarate is an active pharmaceutical ingredient in the Iron Bivalent, Oral Preparations group (B03AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | May 22, 2026 |
| US United States | FDA | 1 | November 8, 2022 |
GBUnited Kingdom· MHRA
6 products
Uses
Prophylaxis and treatment of iron deficiency states. For prophylaxis during pregnancy, a combination of iron and folic acid is usually recommended.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS:
Integra FTM is indicated for the treatment of iron deficiency anemia, and folate deficiency anemia. Integra FTM is indicated in pregnancy for the prevention and treatment of iron deficiency and to supply a maintenance dosage of folic acid.
How to take
Drug interactions
Known interactions involving Ferrous Fumarate. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL127620226 · revised April 10, 2026
- [2]FDA DailyMed · 025fee85-53a8-41… · revised November 8, 2022 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.